GLP-1-Induced AMPK Activation Inhibits PARP-1 and Promotes LXR-Mediated ABCA1 Expression to Protect Pancreatic -Cells Against Cholesterol-Induced Toxicity Through Cholesterol Efflux
Why This Connects to Retatrutide and Survodutide Approved GLP-1 drugs are mostly built around GLP-1 as the primary engine
This is when scientists enroll individuals in a clinical trial, provide an intervention, and track outcomes in real time
These medications slow gastric emptying to promote satiety and weight loss, but this mechanism can disrupt normal bowel function
It does not decrease sex drive
Malhotra adds that long-term cost-effectiveness should be evaluated, asking, Is it worth it to put people on these medications, or are there cheaper ways of achieving that same results, which, right now, I dont know what that would be